WUXAY News and Press, Wuxi AppTec Co. Ltd. ADR From 01/07/24

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan PR Newswire...

2023-10-30 14:46:19 ET More on WuXi AppTec Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppTec Financial information for WuXi AppTec For further details see: WuXi AppTec GAAP EPS of RMB 0.94, revenue of RMB 10.67B

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth PR Newswire Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to o...

2023-07-31 15:47:37 ET WuXi AppTec press release ( OTCPK:WUXAY ): Q2 GAAP EPS of RMB1.07. Revenue of RMB9.91B. Free Cash Flow Achieved RMB2,926 Million for the First Half, Turned Positive and Grew Strongly. For further details see: WuXi AppTec GAAP EPS of $1.07, ...

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022 PR Newswire Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5%...

2023-04-24 06:22:24 ET WuXi AppTec press release ( OTCPK:WUXAY ): Q1 GAAP EPS of RMB0.72. Revenue of RMB8.96B (+5.8% Y/Y). For further details see: WuXi AppTec GAAP EPS of RMB0.72, revenue of RMB8.96B

WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022 PR Newswire Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Mi...

2023-03-27 23:00:00 ET Summary Wuxi AppTec’s chemical business doubled last year, but only grew around 40% excluding revenue from Covid-related products and services. The drug outsourcing services company’s net profit fell 47.6% sequentially to 1.44 billion yuan in t...